Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-DCVac + ICIs in ICI-Resistant Advanced NSCLC
NCT06329908Phase 1Recruiting
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LG002 in non-small cell lung cancer (NSCLC). Primary endpoint: Safety of Neo-DCVac combined with ICIs at 2 years. Started Sep 2023; status: recruiting.
02
Drugs
LG002
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06329908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06329908.